When: Confirmed breakout above $94.50 on volume >7M shares for two consecutive sessions

Then: Add third tranche

Cut starter position to 25% of intended allocation, hold 75% in reserve for a pullback entry to the 50 SMA ($84.96), tighten stop discipline to trigger full review on close below $88.70, execute 25% trim into earnings with pre-committed 50% trim if results are in-line, and commit to scaling up only on confirmed trend resumption.

• Entry at $92.00 with stop at $83.50 represents $8.50 of risk per share (9.2% of entry), making the $96 target only a 0.47-to-1 reward-to-risk ratio, not the claimed 2-to-1
• 90-day return of +19.95% versus 1-year TSR of +2.09% suggests recent strength is a rebound off depressed bases likely to mean-revert, especially into binary earnings catalyst
• The 200 SMA has only one close above it after four months below — weakest possible regime change confirmation
• MACD histogram flip from +0.24 to -0.06 at August 19 swing high of $94.13 is a textbook momentum deceleration signal occurring simultaneously with price failing at resistance
• Double top confirmed with August 19 intraday high of $94.72 and close of $94.13; multiple sessions unable to break above with most recent close at $92.02 forming textbook lower high
• RSI sequence from 75 down to 61 combined with negative MACD histogram signals short-term distribution pattern targeting pullback to 50 SMA at $84.96
• DCF fair value gap is fragile: 50 basis point discount rate change swings fair value by 10-15%; Simply Wall St. model is an automated screen, not bottom-up build
• Higher-for-longer rates compress growth multiples; 3.16% yield acts as structural cap on multiple expansion despite defensive characteristics
• MiniMed Flex single product launch is not thesis-changing for a $36 billion revenue company, especially with Diabetes segment being separated via spin-off
• Boston Scientific cyberattack creates sector-level risk event — hospital procurement slowdowns could shrink entire category, making net effect of MDT share gain ambiguous
• Conservative position sizing: 25% starter vs 33-50% Aggressive; 75% capital held for pullback to 50 SMA at $84.96
• Tighter stop discipline: close below $88.70 (200 SMA) triggers full position review; pre-commit 50% trim on in-line earnings print

→ vs aggressive: Reward-to-risk calculation is inflated — $96 target yields only 0.47-to-1, not 2-to-1; 52-week high is $106.33 and for 2-to-1 the target needs to be $109.00

→ vs aggressive: 200 SMA regime change claim is premature — only one close above after four months below is weakest confirmation, not strongest

→ vs aggressive: MACD histogram flip from +0.24 to -0.06 is not noise but textbook momentum deceleration signal occurring at resistance

→ vs aggressive: DCF 23% gap to fair value is fragile due to assumption sensitivity; Simply Wall St. model is automated screen not bottom-up analysis

→ vs aggressive: 87% probability of no Fed cuts creates discount rate pressure, capping multiple expansion despite 3.16% yield being framed as tailwind

→ vs aggressive: MiniMed Flex catalyst is single product in segment being spun off — cannot be net-added to thesis when segment earnings are being removed

→ vs aggressive: Boston Scientific cyberattack is sector risk event, not pure share-of-wallet opportunity; hospital procurement slowdowns could shrink entire category

BUY: 33% starter position in 90.50-92.50 zone; stop at 83.50; 87.00 add trigger conditional on 200 SMA holding and MACD histogram turning positive; 94.50 breakout add requires volume above 7 million shares and 2 consecutive sessions follow-through; 25% trim pre-earnings; hold post-earnings if guidance supports forward P/E thesis, exit to flat if soft; 30-day time stop if no entry or breakout materializes.

• Structural shift is meaningful: 200 SMA turn, 50 SMA at steepest slope since November, RSI reset from overbought without breaking trend
• Forward P/E of 14.4x versus 18-22x peer med-tech multiple represents real gap; Diabetes separation is announced catalyst, not new risk, making the gap the core thesis
• MACD histogram crossing below zero at lower high after overbought RSI signals immediate-term thrust fading into digestion phase, not trend reversal
• Reward-to-risk from 92.00 entry: 4.00 upside to 96 target versus 8.50 risk = 0.47-to-1, not 2-to-1; requires 109 (above 52-week high of 106.33) for actual 2-to-1
• Binary catalyst with mixed beat signals creates wider outcome dispersion, warranting position sizing discipline rather than assuming favorable distribution
• Conservative's 25% sizing is too defensive for improving setup; 33-50% range is appropriate; 25% essentially becomes watch-and-wait
• Conservative's 50% trim on in-line print is asymmetric wrong direction; 25% pre-print hedge is sensible but holding through print with adaptive post-print response is better
• Higher-for-longer rates don't cap MDT's multiple because income replacement demand, dividend coverage (1.49x FCF), and FCF visibility drive valuation differently than growth stocks
• 87% probability of no Fed cuts reinforces bond-substitute allocation; 3.16% yield with 0.57 beta positions MDT as income-and-quality play
• 30-day time stop: if no breakout above 94.50 or pullback to 87 zone within 30 days, re-evaluate sizing or thesis

→ vs aggressive: Reward-to-risk math is indefensible: from 92.00 entry with 83.50 stop, 96 target is only 0.47-to-1, not 2-to-1; true 2-to-1 requires 109, above the 52-week high of 106.33

→ vs aggressive: Dismissal of MACD histogram flip is wrong; momentum deceleration from 2.64 to 2.30 with histogram crossing below zero at lower high after overbought RSI is a pattern, not noise

→ vs aggressive: Binary catalyst framing is too cute; mixed signals means wider outcome dispersion requiring position sizing discipline, not assumption of favorable distribution

→ vs conservative: 200 SMA confirmation demand leads to chase trade at higher prices after institutional rotation has already priced in regime shift; starter position at inflection is the point of the scaled-in structure

→ vs conservative: Peer multiple argument is circular: Diabetes separation is announced/known catalyst already priced by market, so the gap cannot simultaneously justify avoiding the name and justify the discount

→ vs conservative: Higher-for-longer rates cap multiple expansion for growth stocks but not for MDT, which trades on income replacement demand, dividend coverage, and FCF visibility rather than terminal DCF assumptions

→ vs conservative: 25% position sizing is too defensive; 33-50% range is sensible and 33% reflects actual conviction rather than sizing to feel safe regardless of outcome

→ vs conservative: 50% trim on in-line print is asymmetric in wrong direction; in-line print from defensive name up 20% in 90 days supports structural thesis; trim 25% pre-print hedge instead, hold post-print adaptively